Citizens Raises Rezolute Target to $15 After FDA Guidance

Citizens raised its price target on Rezolute Inc. (NASDAQ: RZLT) to $15.00 from $11.00 while maintaining a Market Outperform rating following positive regulatory feedback from the U.S. Food and Drug Administration regarding ersodetug for congenital hyperinsulinism. The upward revision reflects growing confidence in the drug's path toward commercialization after federal regulators outlined a streamlined review process.

"If the FDA believed an additional clinical trial was necessary, it would have requested one," Citizens analysts noted in a statement regarding the regulatory update.

FDA Feedback and Clinical Trial Path

The positive regulatory development stems from the agency's voluntary review and analysis of clinical data generated from the Phase 3 sunRIZE trial. Following this evaluation, the FDA recommended a pre-Biologics License Application meeting as the direct precursor to submitting a full BLA for ersodetug.

A Biologics License Application is a formal request submitted to the FDA for permission to introduce, or deliver for introduction, a biologic product into interstate commerce. This regulatory milestone allows biotechnology developers to transition from clinical-stage testing to commercial manufacturing and distribution reviews.

Upcoming Clinical Catalysts and Timeline

Beyond the congenital hyperinsulinism program, Rezolute is advancing its clinical pipeline across additional indications. The company expects to report top-line results from the ongoing Phase 3 upLIFT trial targeting tumor-associated hyperinsulinism by the end of 2026.

Market Position and Analyst Sentiment

Analyst target revisions often trigger increased institutional interest in micro-cap and small-cap biotechnology equities, particularly when clinical uncertainty is reduced by direct regulatory alignment. The endorsement from Citizens underscores the perceived commercial potential of ersodetug as the company prepares for its upcoming pre-BLA interactions with federal regulators.